These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 15648944)
1. Anti-angiogenic vaccines as a treatment modality for cancer. Plum SM; Fogler WE Curr Opin Investig Drugs; 2004 Dec; 5(12):1243-6. PubMed ID: 15648944 [TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy of targeting angiogenesis. Hou J; Tian L; Wei Y Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162 [TBL] [Abstract][Full Text] [Related]
3. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045 [TBL] [Abstract][Full Text] [Related]
5. Microtubule-targeting agents in angiogenesis: where do we stand? Pasquier E; Honoré S; Braguer D Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139 [TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic strategies for cancer therapy (Review). Benouchan M; Colombo BM Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440 [TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic drugs: from bench to clinical trials. Quesada AR; Muñoz-Chápuli R; Medina MA Med Res Rev; 2006 Jul; 26(4):483-530. PubMed ID: 16652370 [TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors in the treatment of lung cancer. Sun S; Schiller JH Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557 [TBL] [Abstract][Full Text] [Related]
13. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Dirkx AE; Oude Egbrink MG; Wagstaff J; Griffioen AW J Leukoc Biol; 2006 Dec; 80(6):1183-96. PubMed ID: 16997855 [TBL] [Abstract][Full Text] [Related]
14. Tumor angiogenesis--a potential target in cancer chemoprevention. Bhat TA; Singh RP Food Chem Toxicol; 2008 Apr; 46(4):1334-45. PubMed ID: 17919802 [TBL] [Abstract][Full Text] [Related]
15. Novel approaches in anti-angiogenic treatment targeting endothelial F-actin: a new anti-angiogenic strategy? Thoenes L; Günther M Curr Opin Mol Ther; 2008 Dec; 10(6):579-90. PubMed ID: 19051136 [TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for colorectal cancer: mapping the way. Mocellin S; Lise M; Nitti D Trends Mol Med; 2005 Jul; 11(7):327-35. PubMed ID: 15950539 [TBL] [Abstract][Full Text] [Related]
17. Current immunotherapeutic strategies in renal cell carcinoma. Amato RJ Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554 [TBL] [Abstract][Full Text] [Related]
18. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Shojaei F; Ferrara N Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057 [TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349 [TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development. Phung MW; Dass CR J Pharm Pharmacol; 2006 Feb; 58(2):153-60. PubMed ID: 16451742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]